A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Oka, Tetsuo ^a   Kurozumi, Kazuhiko ^a   Shimazu, Yosuke ^a   Ichikawa, Tomotsugu ^a   Ishida, Joji ^a   Otani, Yoshihiro ^a   Shimizu, Toshihiko ^a   Tomita, Yusuke ^a   Sakaguchi, Masakiyo ^a   Watanabe, Masami ^b   Nasu, Yasutomo ^a   Kumon, Hiromi ^a   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DKK3 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADENOVIRIDAE; ANIMAL; APOPTOSIS; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; GLIOMA; HUMAN; MOUSE; PATHOLOGY; THERAPEUTIC USE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84987846249     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33319     Document Type: Article

References (33)

1. Penas-Prado, M., Gilbert, M. R. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 7, 641-661, doi: 10. 1586/14737140. 7. 5. 641 (2007).
2. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996, doi: 10. 1056/NEJMoa043330 (2005).
3. Tsuji, T., Miyazaki, M., Sakaguchi, M., Inoue, Y., Namba, M. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun 268, 20-24, doi: 10. 1006/bbrc. 1999. 2067 (2000).
4. Tsuji, T. et al. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem Biophys Res Commun 289, 257-263, doi: 10. 1006/bbrc. 2001. 5972 (2001).
5. Abarzua, F. et al. Adenovirus-mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res 65, 9617-9622, doi: 10. 1158/0008-5472. can-05-0829 (2005).
6. Kashiwakura, Y. et al. Down-regulation of inhibition of differentiation-1 via activation of activating transcription factor 3 and Smad regulates REIC/Dickkopf-3-induced apoptosis. Cancer Res 68, 8333-8341, doi: 10. 1158/0008-5472. CAN-08-0080 (2008).
7. Tanimoto, R. et al. REIC/Dkk-3 as a potential gene therapeutic agent against human testicular cancer. Int J Mol Med 19, 363-368 (2007).
8. Wong, Y. C., Wang, X., Ling, M. T. Id-1 expression and cell survival. Apoptosis 9, 279-289 (2004).
9. Mizobuchi, Y. et al. REIC/Dkk-3 induces cell death in human malignant glioma. Neuro Oncol 10, 244-253, doi: 10. 1215/15228517-2008-016 (2008).
10. Shimazu, Y. et al. Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma. Gene Ther 22, 146-154, doi: 10. 1038/gt. 2014. 100 (2015).
11. Watanabe, M. et al. Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. Int J Oncol 34, 657-663 (2009).
12. Uchida, D. et al. Synergistic anti-pancreatic cancer immunological effects by treatment with REIC/DKK3 protein and peripheral blood mononuclear cells. J Gastroenterol Hepatol doi: 10. 1111/jgh. 13259 (2015).
13. Watanabe, M., Nasu, Y., Kumon, H. Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review). Oncol Lett 7, 595-601, doi: 10. 3892/ol. 2013. 1777 (2014).
14. Kim, S. J. et al. Preferentially enhanced gene expression from a synthetic human telomerase reverse transcriptase promoter in human cancer cells. Oncol Rep 16, 975-979 (2006).
15. Song, J. S. Enhanced expression of apoptin by the Myc-Max binding motif and SV40 enhancer for SCLC gene therapy. Biosci Biotechnol Biochem 69, 51-55, doi: 10. 1271/bbb. 69. 51 (2005).
16. Xu, Z. L. et al. Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector. J Control Release 81, 155-163 (2002).
17. Young, J. L., Benoit, J. N., Dean, D. A. Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature. Gene Ther 10, 1465-1470, doi: 10. 1038/sj. gt. 3302021 (2003).
18. Watanabe, M. et al. A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector. Oncol Rep 31, 1089-1095, doi: 10. 3892/or. 2013. 2958 (2014).
19. Tanimoto, R. et al. Down?regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene?therapeutic overexpression of REIC/Dkk-3. International Journal of Cancer 126, 1562-1569 (2010).
20. Chen, S. et al. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol 152, 87-96 (2001).
21. Fukazawa, T. et al. Adenovirus-mediated cancer gene therapy and virotherapy (Review). Int J Mol Med 25, 3-10 (2010).
22. Kojima, T. et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest 119, 3172-3181, doi: 10. 1172/jci38609 (2009).
23. Ueki, H. et al. A novel gene expression system for detecting viable bladder cancer cells. Int J Oncol 41, 135-140, doi: 10. 3892/ijo. 2012. 1417 (2012).
24. Watanabe, M. et al. Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging. Oncol Rep 26, 769-775, doi: 10. 3892/or. 2011. 1371 (2011).
25. Kumon, H. et al. Feasibility of Neoadjuvant Ad-REIC Gene Therapy in Patients with High-Risk Localized Prostate Cancer Undergoing Radical Prostatectomy. Clin Transl Sci 8, 837-840, doi: 10. 1111/cts. 12362 (2015).
26. Kumon, H. et al. Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. Clin Med Insights Oncol 9, 31-38, doi: 10. 4137/CMO. S23252 (2015).
27. Kurozumi, K. et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99, 1768-1781, doi: 10. 1093/jnci/djm229 (2007).
28. Kurozumi, K., Ichikawa, T., Onishi, M., Fujii, K., Date, I. Cilengitide treatment for malignant glioma: current status and future direction. Neurol Med Chir (Tokyo) 52, 539-547 (2012).
29. Fujii, K. et al. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther 20, 437-444, doi: 10. 1038/cgt. 2013. 38 (2013).
30. Onishi, M., Kurozumi, K., Ichikawa, T., Date, I. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Neurol Med Chir (Tokyo) 53, 755-763 (2013).
31. Kurozumi, K., Date, I. [Molecular-Targeted Drug Therapy for Glioma Angiogenesis and Invasion]. No Shinkei Geka 43, 691-701, doi: 10. 11477/mf. 1436203103 (2015).
32. Onishi, M., Ichikawa, T., Kurozumi, K., Date, I. Angiogenesis and invasion in glioma. Brain Tumor Pathol 28, 13-24, doi: 10. 1007/s10014-010-0007-z (2011).
33. Ishida, J. et al. Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Transl Oncol 7, 292-302 e291, doi: 10. 1016/j. tranon. 2014. 02. 016 (2014).